Last reviewed · How we verify
BIIB122
BIIB122 is a monoclonal antibody that targets and inhibits LINGO-1, a protein that suppresses myelin repair and regeneration in the central nervous system.
BIIB122 is a monoclonal antibody that targets and inhibits LINGO-1, a protein that suppresses myelin repair and regeneration in the central nervous system. Used for Multiple sclerosis (remyelination).
At a glance
| Generic name | BIIB122 |
|---|---|
| Also known as | DNL151 |
| Sponsor | Biogen |
| Drug class | LINGO-1 inhibitor monoclonal antibody |
| Target | LINGO-1 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
BIIB122 blocks LINGO-1 (leucine-rich repeat and Ig domain-containing nogo receptor-interacting protein), which is a negative regulator of oligodendrocyte differentiation and myelin formation. By inhibiting LINGO-1, the drug aims to promote remyelination and restore neurological function in demyelinating diseases. This mechanism is intended to support repair and regeneration of damaged myelin in conditions like multiple sclerosis.
Approved indications
- Multiple sclerosis (remyelination)
Common side effects
- Infusion-related reactions
- Infection
- Headache
Key clinical trials
- Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) (PHASE2)
- A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 (PHASE2)
- A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants (PHASE1)
- A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (PHASE3)
- A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants (PHASE1)
- A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects (PHASE1)
- A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIIB122 CI brief — competitive landscape report
- BIIB122 updates RSS · CI watch RSS
- Biogen portfolio CI